Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Seres Therapeutics Shares SER-155 Phase 1b Results in Patients Undergoing allo-HSCT
Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Brand Name : SER-155
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 12, 2024
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Series D Financing
Osteal Therapeutics Raises $50M To Support Lead Candidate Launch
Details : The financing will advance the development of Osteal’s portfolio of therapies, including the submission of NDA and accelerated commercial launch of VT-X7 for treating PJI of the hip and knee.
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Series D Financing
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Vedanta Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Brand Name : VE202
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Vedanta Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Asteroid Partners
Deal Size : $23.0 million
Deal Type : Series C Financing
Osteal Therapeutics Closes $23M Series C Financing
Details : The proceeds will support NDA submission and preparation for commercial launch of company's VT-X7, a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin, for periprosthetic joint...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Asteroid Partners
Deal Size : $23.0 million
Deal Type : Series C Financing
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SER-155 composition aims to decrease the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infe...
Brand Name : SER-155
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 08, 2023
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 07, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2022
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models.
Brand Name : SER-155
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : HM Capital
Deal Size : $30.0 million
Deal Type : Series B Financing
Details : The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 08, 2022
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : HM Capital
Deal Size : $30.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?